Celiac artery adjuvant chemotherapy. Results of a prospective trial

• Published in: International journal of pancreatology Vol. 21; no. 1; pp. 65 - 69
• Main Authors: Link, K H, Gansauge, F, Rilinger, N, Beger, H G
• Format: Journal Article
• Language: English
• Published: United States 01.02.1997
• Subjects: Adult; Aged; Celiac Artery; Chemotherapy, Adjuvant; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - mortality; Prospective Studies
• ISSN: 0169-4197; 2363-5134
• DOI: 10.1007/BF02785922

Celiac artery infusion (CAI) seems to be a qualified and successful method for adjuvant treatment of pancreatic cancer. To improve the dismal prognosis of resected pancreatic cancer patients, we performed postoperative regional chemotherapy via the celiac axis. From 1994-1995, 20 patients with pancreatic cancer (18 ductal adenocarcinoma, 2 cystadenocarcinoma) received adjuvant celiac axis intra-arterial infusions (CAI) after resection of their tumors. Sixteen patients had macroscopically complete tumor removal (R0/R1 resection, 80% of the patients), whereas four patients had gross residual disease remaining after resection (R2 resection, 20% of the patients). Postoperative tumor stages were UICC I in 1 patient, UICC II in 3 patients, and UICC III in 16 patients. CAI was performed for six postoperative cycles via catheters placed into the celiac artery using Seldinger's technique. The chemotherapeutic protocol consisted of mitoxantrone (Novantron), Wyeth-Lederle (Münster, Germany) 10 mg/m2 (d 1), folinic acid (Leucovorin, Wyeth-Lederle, or Rescuvolin, Medac, Hamburg, Germany) 170 mg/m2 for 10 min, followed by 5-FU (Fluoroblastin, Farmitalia, Freiburg, Germany) 600 mg/m2 for 120 min (d 2-4), and Cisplatin (Cisplatin-medac, Medac) 60 mg/m2 (d 5). The cycles were repeated after a rest period of 4 wk. Cisplatin infusions were accompanied by supportive antiemetic (8 mg Tropisetrone i.v. [Navoban, Sandoz, Nürnberg, Germany] and 8 mg Dexametason i.v.) and diuretic measures. Toxicity WHO III occurred in 8% of 100 cycles, and no toxic side effects WHO IV were encountered. The median survival of 21 mo in the treated group was nearly twice as long as the 9.3 mo of a historical matched control group (p < 0.0003). CAI seems to be a qualified and successful method for adjuvant treatment of pancreatic cancer.